December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.570 +0.040 (+1.58%)
Streaming Delayed Price Updated: 10:59 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
22 23 Next >
News headline image
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Where Will Iovance Biotherapeutics Stock Be in 5 Years? ↗
Is this rising healthcare stock a good buy right now? 
Via The Motley Fool
News headline image
The Top 3 Biotech Stocks to Buy in April 2024 ↗
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances. 
Via InvestorPlace
News headline image
Is Iovance Biotherapeutics Stock a Buy Now? ↗
Let's find out if this biotech can keep up its recent momentum. 
Via The Motley Fool
News headline image
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
3 Millionaire-Maker Biotech Stocks ↗
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street ↗
Catalysts lie ahead for both of these companies. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
News headline image
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics ↗
These companies are in the early days of their growth stories. 
Via The Motley Fool
News headline image
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street ↗
Find out why investment banks up and down Wall Street have big expectations for these stocks. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead ↗
This company's growth story is about to get moving with gusto. 
Via The Motley Fool
News headline image
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? ↗
Its revenue is set to grow, and one of its trials is no longer paused. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst ↗
With its first approval in hand, attention is now on the top line. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Could Iovance Biotherapeutics Stock Help You Become a Millionaire? ↗
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio? 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Got Trounced on Thursday ↗
A robust rally ended abruptly with the publication of the company's latest fundamentals. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy? ↗
More gains might be on the way for this high-flying biotech stock. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.